Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer

Di Wu, Cristiane J. Gomes Lima, Gary Bloom, Kenneth D. Burman, Leonard Wartofsky and Douglas Van Nostrand
Journal of Nuclear Medicine March 2020, 61 (3) 397-404; DOI: https://doi.org/10.2967/jnumed.119.230730
Di Wu
1MedStar Health Research Institute, Hyattsville, Maryland
2Nuclear Medicine Research, MedStar Washington Hospital Center, Washington, District of Columbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiane J. Gomes Lima
1MedStar Health Research Institute, Hyattsville, Maryland
3Division of Endocrinology, MedStar Washington Hospital Center, Washington, District of Columbia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Bloom
4ThyCa: Thyroid Cancer Survivors’ Association, Inc., New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth D. Burman
3Division of Endocrinology, MedStar Washington Hospital Center, Washington, District of Columbia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonard Wartofsky
1MedStar Health Research Institute, Hyattsville, Maryland
3Division of Endocrinology, MedStar Washington Hospital Center, Washington, District of Columbia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Van Nostrand
1MedStar Health Research Institute, Hyattsville, Maryland
2Nuclear Medicine Research, MedStar Washington Hospital Center, Washington, District of Columbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Additional Files
    • View popup
    TABLE 1

    Demographics of All Respondents

    1997–2009 (n = 1,258)2011–2018 (n = 1,111)
    Questionn%n%P
    Sex0.954
     Total answers1,2501,105
     Female1,14191.281,00891.22
    Age at 131I therapy (y), mean ± SD44 ± 11 (range, 18–85)—45 ± 12 (range, 18–80)—0.004
    Level of education0.014
     Total answers1,2531,066
     Elementary school00.00%00.00%
     Middle school20.16%20.19%
     High school25320.19%15614.63%
     College66252.83%61357.50%
     Graduate school33626.82%29527.67%
    • View popup
    TABLE 2

    131I Therapies in All Respondents

    1997–2009 (n = 1,258)2011–2018 (n = 1,111)
    Questionn%n%P
    131I therapies<0.001
     Total answers1,2581,107
     189370.99%89881.12%
     225220.03%15413.91%
     3745.88%373.34%
     4211.67%90.81%
     5 or more181.43%90.81%
    Most recent 131I therapy activity<0.001
     Total answers872858
     <1.11 GBq (<30 mCi)515.86%303.50%
     1.11–1.8 GBq (30–49 mCi)434.94%738.51%
     1.85–2.74 GBq (50–74 mCi)485.51%778.97%
     2.78–36.6 GBq (75–99 mCi)718.15%859.91%
     3.7–5.51 GBq (100–149 mCi)29333.64%30835.90%
     5.55–7.36 GBq (150–199 mCi)26830.77%20724.13%
     7.4–9.2 GBq (200–249 mCi)606.89%364.20%
     9.25–11.06 GBq (250–299 mCi)161.84%161.86%
     ≥11.1 GBq (≥300 mCi)212.41%101.17%
    Type of treatment facility0.336
     Total answers1,2471,045
     Outpatient nonhospital13310.67%1049.95%
     Community hospital, small1159.22%878.33%
     Community hospital, large65252.29%58856.27%
     University hospital33426.78%26124.98%
     Veterans Administration hospital60.48%30.29%
     Military hospital70.56%20.19%
    Decision on inpatient/outpatient 131I therapy*<0.001
     Total answers1,2481,098
     Prescribed activity of 131I < 1.22 GBq (<33 mCi)1048.33%383.46%
     Physician made decision94775.88%57752.55%
     Patient was involved in decision14111.30%14713.39%
     Inpatient 131I therapy was not authorized by insurance675.37%555.01%
     Patient completed questionnaire on current living situation27522.04%322.91%
     No discussion56345.11%47443.17%
    Worry about radiation exposure<0.001
     Total answers1,1891,108
     1, none/negligible19216.15%1049.39%
     2, little worried17214.47%38835.02%
     3, moderate/nervous/anxious30825.90%41837.73%
     4, high/really worried23719.93%16715.07%
     5, very high/panicked28023.55%312.80%
    • ↵* More than 1 answer was possible for this question.

    • View popup
    TABLE 3

    Timing and Personnel for Radiation Safety Discussion, Instructions, and Patient Compliance

    1997–20092011–2018
    Questionn%n%P
    When was radiation safety first discussed?
     Total answersNot asked563
     When 131I therapy appointment was made38067.50%
     On day of 131I therapy but before 131I was administered16128.60%
     After 131I therapy71.24%
     Never152.66%
    Who held radiation safety discussion?*
     Total answersNot asked568
     Doctor who referred for 131I therapy28049.30%
     Staff at 131I treatment facility45680.28%
     ThyCa356.16%
     Other417.22%
    Opportunity to adjust instructions based on patient’s current situation?
     Total answersNot asked473
     Yes31566.60%
    When were RSIs delivered?*
     Total answersNot asked564
     Before day of 131I therapy41874.11%
     On day of 131I therapy but before 131I was administered41974.29%
     After 131I therapy10518.62%
     Never71.24%
    Who orally delivered RSIs?*<0.001
     Total answers1,2251,084
     Nuclear medicine physician65653.55%46843.17%
     Radiation oncologist or radiation therapist23619.27%11210.33%
     Endocrinologist28623.35%26824.72%
     Nuclear medicine staff (e.g., nurse or technologist)42234.45%65660.52%
     Radiation safety staff (e.g., physicist or technologist)21217.31%16715.41%
     Nurse17113.96%1049.59%
     Administrator221.80%141.29%
     Other211.71%343.14%
    Patient signature on form declaring compliance?0.1022
     Total answers982843
     Yes86187.68%71785.05%
    Self-assessment of overall compliance<0.001
     Total answers1,1941,105
     Complete1,01384.84%1,03493.57%
     Almost complete16713.99%676.06%
     Half90.75%20.18%
     Almost none30.25%20.18%
     None20.17%00.00%
    • ↵* More than 1 answer was allowed for this question.

    • View popup
    TABLE 4

    RSIs Given to Patients for 131I Therapy

    RSIs1997–20092011–2018
    OralWrittenOralWritten
    Received oral or written RSIs97.56% (1,198/1,228)95.73% (1,144/1,195)95.23% (1,039/1,091)90.47% (987/1,091)
    To reduce to as low as is reasonably achievable any radiation exposure from 131I to other individuals96.56% (1,179/1,221)93.86% (1,101/1,173)96.34% (1,053/1,093)91.70% (972/1,060)
    To discontinue breast feeding (if applicable) and be aware of potential consequences of noncompliance90.66% (359/396)87.61% (396/452)91.04% (183/201)87.96% (190/216)
    To be aware of detectable amounts of 131I that may set off security alarms at places such as airports72.40% (837/1,156)69.82% (768/1,100)76.97% (792/1,029)73.41% (704/959)
    To keep the name and telephone number of person or department to call if any questions about 131I treatment72.72% (829/1,140)76.42% (846/1,107)59.98% (586/977)69.95% (668/955)
    To not travel by mass transportation for at least first days82.90% (727/877)
    To sleep alone in room for at least first night97.70% (933/955)
    To live alone for at least first 2 d68.88% (686/996)
    To have few visits by family or friends for at least first 2 d87.16% (869/997)
    To maintain good distance from others for at least first 2 d97.03% (980/1,010)
    To not travel on long car trips with others for at least first 2 d88.97% (871/979)
    To not share bathroom for at least first 2 d91.47% (912/997)
    To drink plenty of water for at least first 2 d93.58% (918/981)
    • The last 8 RSIs were not available in the 1997–2009 survey.

    • View popup
    TABLE 5

    Outpatient Release and Lodging Data

    1997–20102011–2018
    Questionn%n%P
    Release time after 131I administration0.027
     Total answers1,071941
     Immediately (<30 min)76871.71%73277.79%
     30–59 min18717.46%13013.82%
     1–2 h898.31%505.31%
     2–3 h161.49%192.02%
     3–4 h50.47%30.32%
     4–5 h10.09%50.53%
     5–6 h30.28%00.00%
     6–7 h10.09%20.21%
     7–8 h00.00%00.00%
     8 h or more10.09%00.00%
    Lodging<0.001
     Total answers1,125*953
     Own home95584.89%79589.13%
     Relative’s home1079.51%626.95%
     Motel, hotel, rental house, or boarding house524.62%353.92%
     Nursing home10.09%00.00%
     Other221.96%616.84%
    • ↵* More than 1 answer was allowed for this question.

    • View popup
    TABLE 6

    Outpatient Transportation Data

    1997–20102011–2018
    Questionn%n%P
    Mode of transportation0.862
     Total answers1,079955*
     Car1,05397.59%93898.22%
     Taxi131.20%121.26%
     Bus00.00%20.21%
     Train10.09%10.10%
     Subway30.28%00.00%
     Airplane00.00%20.21%
     Other90.83%121.26%
    Duration of travel0.964
     Total answers1,079937
     <1 h84378.13%72076.84%
     1–2 h17616.31%16317.40%
     2–3 h373.43%384.06%
     3–4 h141.30%90.96%
     4–5 h30.28%30.32%
     5–6 h40.37%20.21%
     6–7 h10.09%00.00%
     7–8 h00.00%20.21%
     >8 h10.09%00.00%
    Number of persons within 1 m (3 ft)0.046
     Total answers1,067915
     056653.05%55560.66%
     144441.61%33536.61%
     2353.28%202.19%
     390.84%20.22%
     420.19%00.00%
     510.09%00.00%
     630.28%00.00%
     700.00%00.00%
     8 or more70.66%30.33%
    • ↵* More than 1 answer was allowed for this question.

Additional Files

  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (3)
Journal of Nuclear Medicine
Vol. 61, Issue 3
March 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
Di Wu, Cristiane J. Gomes Lima, Gary Bloom, Kenneth D. Burman, Leonard Wartofsky, Douglas Van Nostrand
Journal of Nuclear Medicine Mar 2020, 61 (3) 397-404; DOI: 10.2967/jnumed.119.230730

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
Di Wu, Cristiane J. Gomes Lima, Gary Bloom, Kenneth D. Burman, Leonard Wartofsky, Douglas Van Nostrand
Journal of Nuclear Medicine Mar 2020, 61 (3) 397-404; DOI: 10.2967/jnumed.119.230730
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Theranostics

  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • 131I therapy
  • differentiated thyroid cancer
  • radiation safety
  • nonprivate residence
SNMMI

© 2025 SNMMI

Powered by HighWire